Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
27,795,576
-
Number of holders
-
116
-
Total 13F shares, excl. options
-
22,229,470
-
Shares change
-
+2,057,022
-
Total reported value, excl. options
-
$498,975,777
-
Value change
-
+$42,806,085
-
Put/Call ratio
-
2.42%
-
Number of buys
-
63
-
Number of sells
-
-38
-
Price
-
$22.45
Significant Holders of Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share (AXDX) as of Q3 2017
149 filings reported holding AXDX - Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share as of Q3 2017.
Accelerate Diagnostics, Inc. - Common Stock, par value $0.001 per share (AXDX) has 116 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 22,229,470 shares
of 27,795,576 outstanding shares and own 79.97% of the company stock.
Largest 10 shareholders include Birchview Capital, LP (2,183,795 shares), CREDIT SUISSE AG/ (1,821,503 shares), BlackRock Inc. (1,665,180 shares), VANGUARD GROUP INC (1,289,479 shares), CANNELL PETER B & CO INC (1,096,239 shares), Polar Capital LLP (1,037,666 shares), Miura Global Management, LLC (960,000 shares), BLAIR WILLIAM & CO/IL (947,293 shares), ArrowMark Colorado Holdings LLC (860,482 shares), and Nuveen Asset Management, LLC (729,498 shares).
This table shows the top 116 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.